{"mainPropery":{"diseaseId":11901,"diseaseName":"Juvenile amyotrophic lateral sclerosis","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/11901/juvenile-amyotrophic-lateral-sclerosis","synonyms":["Amyotrophic lateral sclerosis, juvenile","JALS","Juvenile Charcot disease","Juvenile Lou Gehrig disease"],"synonyms-with-source":[{"name":"Amyotrophic lateral sclerosis, juvenile","source":""},{"name":"JALS","source":"Orphanet"},{"name":"Juvenile Charcot disease","source":"Orphanet"},{"name":"Juvenile Lou Gehrig disease","source":"Orphanet"}],"identifiers":[{"identifierType":"ORPHANET","identifierId":"300605"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"}],"organizations":[{"resourceID":512,"resourceName":"Muscular Dystrophy Association - ALS Division","abbreviation":"","address1":"3300 East Sunrise Drive","address2":"Amyotrophic Lateral Sclerosis","address3":"","address4":"","address5":"","city":"Tucson","state":"AZ","zip":"85718-3208","country":"United States","phone":"800-572-1717 or 800-344-4863","tty":"","tollFree":"","fax":"520-529-5300","email":"mda@mdausa.org","url":"https://www.mda.org/disease/amyotrophic-lateral-sclerosis","freeText":""},{"resourceID":510,"resourceName":"Amyotrophic Lateral Sclerosis Society of Canada","address1":"265 Yorkland Boulevard","address2":"Suite 300","address3":"Toronto Ontario M2J 1S5","address4":"","address5":"","city":"","state":"","zip":"","country":"Canada","phone":"800-267-4ALS (800-267-4257)","tty":"","tollFree":"","fax":"416-497-1256","email":"SI@als.ca","url":"http://www.als.ca"},{"resourceID":2652,"resourceName":"The ALS Association","abbreviation":"","address1":"1275 K Street, N.W.","address2":"Suite 250","address3":"","address4":"","address5":"","city":"Washington, DC","state":"","zip":"20005","country":"","phone":"202-407-8580","tty":"","tollFree":"1-800-782-4747","fax":"202-464-8869","email":"alsinfo@alsa-national.org","url":"http://www.alsa.org","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/omim?term=%28juvenile[Title]%29%20AND%20amyotrophic%20lateral%20sclerosis[Title]' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed?term=%28juvenile[Title/Abstract]%20AND%20amyotrophic[Title/Abstract]%20AND%20lateral[Title/Abstract]%20AND%20sclerosis[Title/Abstract]%29%20AND%20%28%222003/07/09%22[PDat]%20%3A%20%222013/07/05%22[PDat]%29&amp;amp;cmd=DetailsSearch' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Juvenile amyotrophic lateral sclerosis. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300605' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1742,"resourceId":2896,"resourceName":"RDCRN - Clinical Research in Amyotrophic Lateral Sclerosis and Related Disorders for Therapeutic Development","descriptionText":"The <a target=\"_blank\" href=\"https://www.rarediseasesnetwork.org/CREATE/index.htm\">Clinical Research in Amyotrophic Lateral Sclerosis and Related Disorders for Therapeutic Development (CREATE) Consortium</a> is an integrated group of academic medical centers, patient support organizations, and clinical research resources dedicated to conducting clinical research involving sporadic and familial forms of amyotrophic lateral sclerosis, frontotemporal dementia (FTD), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), and progressive muscular atrophy (PMA). The CREATE Consortium has a contact registry for patients who wish to be contacted about clinical research opportunities and updates on the progress of the research projects.\r\n<br />\r\n<br />\r\nFor more information on the registry see: <a target=\"_blank\" href=\"https://www.rarediseasesnetwork.org/registry/index.htm\">https://www.rarediseasesnetwork.org/registry/index.htm</a>","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/Orphanet:300605' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2159,"resourceId":3367,"resourceName":"Patient Services, Inc (PSI)","descriptionText":"<a href='https://www.patientservicesinc.org/patients/access-program' target='_blank'>Patient Services, Inc (PSI)</a> provides financial support and guidance for qualified patients with specific chronic diseases. PSI helps patients find solutions to the social and economic problems confronting patients with chronic conditions.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"}],"overviewQuestion":{"questionId":6950,"questionText":"What is juvenile amyotrophic lateral sclerosis?","answerText":"<strong>Juvenile amyotrophic lateral sclerosis</strong> (JALS) is a rare&nbsp;<a href=\"https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Motor-Neuron-Diseases-Fact-Sheet\" target=\"_blank\">motor neuron disease</a> characterized by progressive degeneration of upper and lower motor neurons. Motor neurons are nerve cells that control voluntary muscle activity.[13408] Symptoms of JALS typically begin before age 25, but often in early childhood.[13408][13409] Symptoms include facial spasticity, dysarthria, and a spastic gait (manner of walking). Some people have uncontrolled laughter and weeping, mild wasting of the legs and hands, bladder dysfunction, and/or sensory disturbances.[13408] The disease is usually slowly progressive but rate of progression varies.[13409] People with JALS may become unable to move by age 12 to age 50.[13408]<br />\r\n<br />\r\nJALS includes several subtypes, distinguished by the specific variations (mutations) in any of several genes, including:[13408][13409]\r\n<ul>\r\n    <li><span style=\"font-family: Arial, sans-serif; color: black;\"><a href=\"https://www.omim.org/entry/205100\" target=\"_blank\">ALS2</a> caused by mutations in the </span><em><span style=\"font-family: Verdana, sans-serif; color: black;\"><a href=\"https://ghr.nlm.nih.gov/gene/ALS2\" target=\"_blank\"><span style=\"color: blue;\">ALS2</span></a></span></em><span style=\"font-family: Verdana, sans-serif; color: black;\">&nbsp;gene</span></li>\r\n    <li><span style=\"font-family: Verdana, sans-serif; color: black;\"><a href=\"https://omim.org/entry/614373\" target=\"_blank\">ALS16</a> caused by mutations in the<em> <a href=\"https://ghr.nlm.nih.gov/gene/SIGMAR1\" target=\"_blank\"><span style=\"color: blue;\">SIGMAR1</span></a></em></span><span style=\"font-family: Verdana, sans-serif; color: black;\">&nbsp;gene</span></li>\r\n    <li><span style=\"font-family: Verdana, sans-serif; color: black;\"><a href=\"https://www.omim.org/entry/602099\" target=\"_blank\">ALS5</a> caused by mutations in the<em> <a href=\"https://ghr.nlm.nih.gov/gene/SPG11\" target=\"_blank\"><span style=\"color: blue;\">SPG11</span></a></em></span><span style=\"font-family: Verdana, sans-serif; color: black;\">&nbsp;gene</span></li>\r\n    <li><span style=\"font-family: Verdana, sans-serif; color: black;\"><a href=\"https://omim.org/entry/602433\" target=\"_blank\">ALS4</a> caused by mutation in the<em> <a href=\"https://ghr.nlm.nih.gov/gene/SETX\" target=\"_blank\"><span style=\"color: blue;\">SETX</span></a></em></span><span style=\"font-family: Verdana, sans-serif; color: black;\">&nbsp;gene</span></li>\r\n</ul>\r\n<span style=\"font-family: Verdana, sans-serif; color: black;\">There are some reports of&nbsp; JALS caused by mutations in the&nbsp;&nbsp;</span><span style=\"font-family: Verdana, sans-serif; color: black;\"><em><span style=\"color: blue;\"><a href=\"https://ghr.nlm.nih.gov/gene/UBQLN2\" target=\"_blank\">UBQLN2</a>&nbsp;</span></em></span><span style=\"font-family: Verdana, sans-serif; color: black;\">(related to ALS15), <em><a href=\"https://ghr.nlm.nih.gov/gene/FUS\" target=\"_blank\"><span style=\"color: blue;\">FUS</span></a></em></span><span style=\"font-family: Verdana, sans-serif; color: black;\">&nbsp;(related to ALS6) and&nbsp;</span><em><a href=\"https://ghr.nlm.nih.gov/gene/TARDBP\" target=\"_blank\"><span style=\"color: blue;\">TARDBP</span></a></em><span style=\"font-family: Verdana, sans-serif;\">&nbsp;(related to ALS10) genes.[13408][13409][14655][14656]</span>\r\n<p style=\"text-align: left;\">Mutations may be inherited from a parent or may occur for the first time in a person with the disease.[13409] Inheritance may be autosomal recessive or autosomal dominant depending on the gene involved.[13408][13409]<br />\r\n<br />\r\nThere is no specific treatment for JALS. Management generally involves physical and occupational therapy to promote mobility and independence.[13408]<br />\r\n<br />\r\n</p>","dateModified":"2018-05-24T00:00:00"},"basicQuestions":[{"questionId":6952,"questionText":"What are the signs and symptoms of juvenile amyotrophic lateral sclerosis?","answerText":"Signs and symptoms of juvenile amyotrophic lateral sclerosis (JALS) begin before age 25 (which defines the juvenile form). All people with JALS eventually develop symptoms of both upper and lower motor dysfunction, but the symptoms, rate of progression, and severity varies from person to person.[6098]<br />\r\n<br />\r\nSigns of upper&nbsp;motor neuron dysfunction include the <a href=\"https://medlineplus.gov/ency/article/003294.htm\" target=\"_blank\">Babinski sign</a>, muscle spasms, and overactive reflexes (hyperreflexia). Lower motor neuron signs include muscle wasting (atrophy), weakness, and muscle twitches.[6098] Facial spasticity, slurred speech (dysarthria), and a spastic&nbsp; gait are common. Some people with JALS have uncontrolled laughter or crying,  bladder dysfunction, and/or sensory disturbances.[13408] Cognitive function is not affected.[6098] The disease is usually slowly progressive but the rate of progression varies.[13409] People with JALS may become unable to move by age 12 to age 50.[13408]","dateModified":"2017-05-11T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":6098,"authors":"Orban P, Devon RS, Hayden MR, Leavitt BR","articleTitle":"Juvenile Amyotrophic Lateral Sclerosis","bookWebsiteJournalTitle":"Handbook of Clinical Neurology","date":"2007","volume":"82(3)","pages":"301-312","url":"http://www.ncbi.nlm.nih.gov/pubmed/18808900","authors2":"","placeOfPublication":"","publisher":"Elsevier"},{"referenceId":13408,"authors":"Bertini E","articleTitle":"Juvenile amyotrophic lateral sclerosis","bookWebsiteJournalTitle":"Orphanet","date":"February, 2014","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300605","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":13409,"authors":"Liu ZJ, Lin HX, Liu GL, Tao QQ, Ni W, Xiao BG, Wu ZY","articleTitle":"The investigation of genetic and clinical features in Chinese patients with juvenile amyotrophic lateral sclerosis","bookWebsiteJournalTitle":"Clin Genet","date":"April, 2017","volume":"[Epub ahead of print]","pages":"","url":"https://www.ncbi.nlm.nih.gov/pubmed/28429524","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":6951,"questionText":"What causes juvenile amyotrophic lateral sclerosis?","answerText":"Juvenile amyotrophic lateral sclerosis (JALS) can be caused by mutations in any of several genes including <em><a href=\"https://ghr.nlm.nih.gov/gene/ALS2\" target=\"_blank\">ALS2</a></em>, <em><a href=\"https://ghr.nlm.nih.gov/gene/SIGMAR1\" target=\"_blank\">SIGMAR1</a></em>, <em><a href=\"https://ghr.nlm.nih.gov/gene/SPG11\" target=\"_blank\">SPG11</a></em>, <em><a href=\"https://ghr.nlm.nih.gov/gene/SETX\" target=\"_blank\">SETX</a></em>, <em><a href=\"https://ghr.nlm.nih.gov/gene/SOD1\" target=\"_blank\">SOD1</a></em>, <em><a href=\"https://ghr.nlm.nih.gov/gene/UBQLN2\" target=\"_blank\">UBQLN2</a></em>, <em><a href=\"https://ghr.nlm.nih.gov/gene/FUS\" target=\"_blank\">FUS</a>, </em>and <em><a href=\"https://ghr.nlm.nih.gov/gene/TARDBP\" target=\"_blank\">TARDBP</a></em>.[13408][13409] Mutations bay be inherited from a parent or occur for the first time in a person with the disease.[13409] Inheritance may be autosomal recessive or autosomal dominant depending on the gene involved.[13408][13409]<br />\r\n<br />\r\nGenes responsible for amyotrophic lateral sclerosis (ALS) are important for normal functioning of motor neurons and other cells. It isn't always clear how mutations in these genes cause ALS.[133]","dateModified":"2017-05-11T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":133,"authors":"","articleTitle":"Amyotrophic Lateral Sclerosis","bookWebsiteJournalTitle":"Genetics Home Reference","date":"March, 2016","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition=amyotrophiclateralsclerosis","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":13408,"authors":"Bertini E","articleTitle":"Juvenile amyotrophic lateral sclerosis","bookWebsiteJournalTitle":"Orphanet","date":"February, 2014","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300605","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":13409,"authors":"Liu ZJ, Lin HX, Liu GL, Tao QQ, Ni W, Xiao BG, Wu ZY","articleTitle":"The investigation of genetic and clinical features in Chinese patients with juvenile amyotrophic lateral sclerosis","bookWebsiteJournalTitle":"Clin Genet","date":"April, 2017","volume":"[Epub ahead of print]","pages":"","url":"https://www.ncbi.nlm.nih.gov/pubmed/28429524","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":6953,"questionText":"How might juvenile amyotrophic lateral sclerosis be treated?","answerText":"There is no specific treatment for juvenile amyotrophic lateral sclerosis (JALS). Management generally involves strategies to to relieve symptoms and to promote mobility and independence.[13408] Medications may include those for specific symptoms such as fatigue and muscle cramping. Physical therapy and special equipment can be helpful. Multidisciplinary teams of various health care professionals can help to develop personalized treatment plans.[134]<br />\r\n<p>&nbsp;</p>","dateModified":"2017-05-11T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":134,"authors":"Kinsley L, Siddique T","articleTitle":"Amyotrophic Lateral Sclerosis Overview","bookWebsiteJournalTitle":"GeneReviews","date":"February 12, 2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1450/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":13408,"authors":"Bertini E","articleTitle":"Juvenile amyotrophic lateral sclerosis","bookWebsiteJournalTitle":"Orphanet","date":"February, 2014","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=300605","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":5786,"relatedDiseaseName":"Amyotrophic lateral sclerosis","relation":"Parent","isRare":true,"hasGardPage":true},{"relatedDiseaseId":10497,"relatedDiseaseName":"Amyotrophic lateral sclerosis type 10","relation":"Child","isRare":true,"hasGardPage":false},{"relatedDiseaseId":9470,"relatedDiseaseName":"Amyotrophic lateral sclerosis type 2","relation":"Child","isRare":true,"hasGardPage":false},{"relatedDiseaseId":10502,"relatedDiseaseName":"Amyotrophic lateral sclerosis type 4","relation":"Child","isRare":true,"hasGardPage":false},{"relatedDiseaseId":10503,"relatedDiseaseName":"Amyotrophic lateral sclerosis type 5","relation":"Child","isRare":true,"hasGardPage":false},{"relatedDiseaseId":9874,"relatedDiseaseName":"Amyotrophic lateral sclerosis type 6","relation":"Child","isRare":true,"hasGardPage":false}],"gardCases":[],"news":[{"newsId":680,"dateCreated":"2020-08-28T12:03:00","publishDate":"2020-09-01T00:00:00","title":"NIH Announces New Transformative Research Award Program for ALS","description":"The National Institutes of Health plans to invest $25 million over 5 years in a new program to spur innovative research on amyotrophic lateral sclerosis (ALS), a progressive and fatal neurological disease that weakens and eventually paralyzes voluntary muscles. Accelerating Leading-edge Science in ALS (ALS2) aims to answer critical questions about this disease.","url":"https://www.nih.gov/news-events/news-releases/nih-announces-new-transformative-research-award-program-als","lastModified":"2020-09-03T13:45:00","isFeatured":false},{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":8521,"phenoTypeName":"Abnormal pyramidal sign","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13748,"phenoTypeName":"Abnormal upper motor neuron morphology","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13679,"phenoTypeName":"Amyotrophic lateral sclerosis","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":8703,"phenoTypeName":"Dysarthria","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13575,"phenoTypeName":"EMG abnormality","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":9379,"phenoTypeName":"Gait disturbance","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":10649,"phenoTypeName":"Hyperreflexia","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":8711,"phenoTypeName":"Spasticity","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":14592,"phenoTypeName":"Decreased muscle mass","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13863,"phenoTypeName":"Pseudobulbar behavioral symptoms","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5,"phenoTypeName":"Abnormality of the bladder","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":14147,"phenoTypeName":"Sensory neuropathy","frequencyText":"Occasional","percentRanges":"5%-29%"}],"medicalProducts":[],"EncodedName":"Juvenile_amyotrophic_lateral_sclerosis"}